Testing the accelerator hypothesis: a new approach to type 1 diabetes prevention (adAPT 1)

2015 ◽  
Vol 18 (1) ◽  
pp. 3-5 ◽  
Author(s):  
T. Wilkin ◽  
S. Greene ◽  
R. McCrimmon
Diabetes Care ◽  
2006 ◽  
Vol 29 (3) ◽  
pp. 643-649 ◽  
Author(s):  
J. M. Sosenko ◽  
J. P. Palmer ◽  
C. J. Greenbaum ◽  
J. Mahon ◽  
C. Cowie ◽  
...  

2017 ◽  
Vol 15 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Flavia Prodam ◽  
Annalisa Chiocchetti ◽  
Umberto Dianzani

2021 ◽  
Author(s):  
Michael G Voss ◽  
David D Cuthbertson ◽  
Mario M Cleves ◽  
Ping Xu ◽  
Carmella Evans-Molina ◽  
...  

<b>Objective:</b> To assess the progression of type 1 diabetes using time to peak glucose or C-peptide during oral glucose tolerance tests (OGTTs) in autoantibody positive (Ab+) relatives of people with type 1 diabetes. <p><b>Methods:</b> We examined 2-hour OGTTs of participants in the Diabetes Prevention Trial Type 1 (DPT-1) and TrialNet Pathway to Prevention (PTP) studies. We included 706 DPT-1 participants (Mean±SD age: 13.84±9.53 years; BMI-Z-Score: 0.33±1.07; 56.1% male) and 3,720 PTP participants (age: 16.01±12.33 Years, BMI-Z-Score 0.66±1.3; 49.7% male). Log-rank testing and Cox regression analyses with adjustments (age, sex, race, BMI Z-Score, HOMA-IR and peak Glucose/C-peptide levels, respectively) were performed. </p> <p><b>Results:</b> In each of DPT-1 and PTP, higher 5-year diabetes progression risk was seen in those with time to peak glucose >30 min and time to peak C-peptide >60 min (p<0.001 for all groups), before and after adjustments. In models examining strength of association with diabetes development, associations were greater for time to peak C-peptide versus peak C-peptide value (DPT-1: X<sup>2 </sup>= 25.76 vs. X<sup>2</sup> = 8.62 and PTP: X<sup>2 </sup>= 149.19 vs. X<sup>2</sup> = 79.98; all p<0.001). Changes in the percentage of individuals with delayed glucose and/or C-peptide peaks were noted over time.</p> <p><b>Conclusions: </b>In two independent at risk populations, we show that those with delayed OGTT peak times for glucose or C-peptide are at higher risk of diabetes development within 5 years, independent of peak levels. Moreover, time to peak C-peptide appears more predictive than the peak level, suggesting its potential use as a specific biomarker for diabetes progression. </p>


Diabetes Care ◽  
2008 ◽  
Vol 31 (11) ◽  
pp. 2188-2192 ◽  
Author(s):  
J. M. Sosenko ◽  
J. P. Palmer ◽  
L. Rafkin-Mervis ◽  
J. P. Krischer ◽  
D. Cuthbertson ◽  
...  

2009 ◽  
Vol 10 (3) ◽  
pp. 177-183 ◽  
Author(s):  
Suzanne Bennett Johnson ◽  
Amy E Baughcum ◽  
Lisa E Rafkin-Mervis ◽  
Desmond A Schatz ◽  

Diabetes ◽  
2016 ◽  
Vol 65 (11) ◽  
pp. 3233-3239 ◽  
Author(s):  
Anette-G. Ziegler ◽  
Ezio Bonifacio ◽  
Alvin C. Powers ◽  
John A. Todd ◽  
Leonard C. Harrison ◽  
...  

Diabetes Care ◽  
2007 ◽  
Vol 31 (3) ◽  
pp. 528-533 ◽  
Author(s):  
J. M. Sosenko ◽  
J. P. Krischer ◽  
J. P. Palmer ◽  
J. Mahon ◽  
C. Cowie ◽  
...  

2008 ◽  
Vol 116 (S 01) ◽  
pp. S26-S29 ◽  
Author(s):  
E. Bonifacio ◽  
P. Achenbach ◽  
L. Pan ◽  
A.-G. Ziegler

Sign in / Sign up

Export Citation Format

Share Document